[ad_1]
Hanmi Pharmaceutical introduced on Jan. 28 that it has signed an unique distribution contract with Mexican pharmaceutical firm Laboratorios Sanfer for GLP-1 weight problems drug efeglenatide and the Dafaron household, a diabetes remedy mixture drug.
Hanmi Pharmaceutical will provide completed merchandise of efeglenatide and Hanmi’s consultant diabetes remedy lineup, the Dafaron household (Dafaron tablets and Dafaron Duo sustained-release tablets), whereas Sanfer might be answerable for approval, advertising and marketing, distribution, and gross sales inside Mexico.
Each corporations plan to regularly broaden cooperation on efeglenatide and metabolic illness therapies total, and within the medium to long run, they will even talk about further product introduction and joint advertising and marketing methods.
Ricardo Amtmann, chief govt officer (CEO) of Sanfer, said, “Hanmi Pharmaceutical’s weight problems drug and diabetes remedy lineup have the product capabilities that meet these circumstances,” including, “Via this partnership, we plan to contribute to fixing the issues of weight problems and diabetes, that are quickly growing illnesses in Mexico.”
Park Jae-hyeon, CEO of Hanmi Pharmaceutical, mentioned, “We think about it significant that Hanmi Pharmaceutical’s independently developed GLP-1 collection weight problems and metabolic illness remedy and progressive diabetes remedy lineup can contribute to enhancing the well being of the Mexican individuals.”
In the meantime, Hanmi Pharmaceutical accomplished its software for approval of efeglenatide to the Ministry of Meals and Drug Security on Dec. 17 final yr, and in September final yr, it submitted a Section 3 medical trial plan (IND) for mixture remedy with SGLT-2 inhibitor and metformin, which was authorised on Jan. 21.
Hanmi Pharmaceutical is pursuing enlargement of efeglenatide’s indications past weight problems remedy to the diabetes remedy space, and is continuing with improvement with the aim of weight problems approval within the second half of 2026 and addition of diabetes indications in 2028.
[ad_2]
